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In vitro modulation of cyst formation by a novel tyrosine
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In vitro modulation of cyst formation by a novel tyrosine kinase formation and enlargement of renal collecting tubule
inhibitor. (CT) cysts and hepatic biliary ectasia [2].
Background. Recessively transmitted polycystic kidney dis- The significant morbidity and mortality produced byease (PKD) in many murine models is characterized by the
renal cystic disease have stimulated investigations intoinitial formation of proximal tubular cysts (stage 1), followed
the molecular and cellular basis of renal cyst formationby growth and enlargement of renal collecting tubule (CT)
cysts (stage 2). Previous studies have reported that stage 1 cyst and enlargement. Experimental studies have identified
formation and growth could be manipulated in vitro by using abnormalities of proliferation, fluid secretion and extra-
embryonic kidney explants and newborn explant microslices cellular matrix, structure and biology as important patho-
in organ culture.
physiological processes in PKDs [1–3]. These studies haveMethods. Microslices of postnatal kidneys cultured on Trans-
identified tubular hyperplasia as a necessary factor inwell tissue culture inserts allow experimental manipulation of
stage 2 CT cyst development and growth. This system was used the development and growth of renal cysts in PKD [1].
to test a potential therapeutic compound for treatment of PKD. Additionally, studies into the cellular and molecular
This compound, EKI-785, modulates altered epidermal growth mechanisms of cyst formation have provided insight into
factor receptor (EGFR) expression in CT cysts by inhibition
the role of other genes and proteins that undergo alter-of EGFR autophosphorylation.
ations in expression caused by interactions with mutatedResults. These studies demonstrate that: (a) minor modifi-
cystic genes/gene products. For example, evidence fromcations of the previously described organ culture system permit
successful culture of more mature renal tissue, and (b) cystic a number of studies has demonstrated a potential role
explants treated with EGF and EKI-785 demonstrated a marked for epidermal growth factor receptor (EGFR) and its
reduction in CT cystic lesions compared with cystic explants ligands, epidermal growth factor (EGF) and trans-treated with EGF alone.
forming growth factor-a (TGF-a), in renal epithelial hy-Conclusions. This study suggests that pharmacological strat-
perplasia, cyst development, and enlargement [4–14].egies can be used to decrease EGFR tyrosine kinase activity
and CT cyst formation and enlargement in murine PKD. Recessively transmitted PKD in many murine models
is characterized by the initial formation of proximal tubu-
lar cysts (stage 1), followed by growth and enlargement
Polycystic kidney diseases (PKDs) are genetic abnor- of renal CT cysts (stage 2) [15–17]. We have previously
malities that account for approximately 10% of end-stage reported that stage 1 cyst formation and growth could
renal disease (ESRD) requiring dialysis or transplanta- be manipulated in vitro using embryonic kidney explants
tion [1]. Autosomal dominant PKD (ADPKD) has an and newborn explant microslices in organ culture [11,
estimated incidence of 1 in 500 to 1 in 1000 individuals. 18]. The purpose of our current study was to develop an
Autosomal recessive PKD (ARPKD) has an incidence in vitro organ culture system that would allow experi-
of 1 in 10,000 to 1 in 40,000 and a mortality of 30 to 50% mental manipulation of stage 2 CT cyst development
in the newborn period [2]. Clinically, ARPKD has a wide and growth and to use this system to test a potential
clinical spectrum but is invariantly characterized by the therapeutic compound that targets altered EGFR ex-
pression in CT cysts.
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murine metanephric organ culture system [11, 19–22]. In all experiments, tissue culture medium was replaced
Explants (100 to 150 mm thick slices) of control and stage every 24 hours with freshly prepared medium. Basal
2 postnatal (P-14) kidneys from BPK cystic mice [8, 16] medium and all supplements were obtained from Sigma
were cultured in serum-free, chemically defined medium (St. Louis, MO, USA).
for 120 hours on a Transwell tissue culture insert at 36 6
Determination of growth and tubular proliferation0.58C and 95% humidity in a mixed air–5% CO2 environ-
ment. Growth of metanephric explants was assessed follow-
Collecting tubule cyst growth and regression were ing 120 hours of incubation using the Bradford protein
studied following EGFR stimulation and inhibition. Inhi- microassay [24]. Explant viability was assessed using pre-
bition was accomplished with EKI-785, a tyrosine kinase viously described methods of cellular trypan blue exclu-
inhibitor (TKI) specific for EGF and Erb/B2 receptors sion and neutral red uptake [11]. Three kidneys from
[23]. Tyrosine kinase inhibition was accomplished with each treatment group were used to determine protein
EKI-785, a TKI specific for EGF and Erb/B2 receptors content and viability. Tubular proliferation was evalu-
[23]. This compound covalently binds to EGFR, inhibits ated by a modification of a previously described protocol
kinase activity of the protein (IC50 5 370 6 120 pm), for BrdU labeling [11]. Following 118 hours of culture,
blocks EGF stimulated autophosphorylation of the re- 10 mm BrdU (well in excess of media thymidine concen-
ceptor (IC50 5 5 nm), inhibits cell proliferation, and tration) were added to the culture medium of all groups,
blocks the growth of tumors that overexpress EGFR [24]. and explants were harvested at 120 hours. Following
Explants from P-14 BPK (cystic) kidneys and control routine histological preparation (discussed later here), 8
(unaffected) kidneys were divided into four experimen- to 10 3 mm serial sections of six explants were evaluated
tal groups for analysis: explants cultured in basal medium for BrdU labeling, expressed as BrdU-positive cells per
alone, explants cultured in basal medium supplemented 500 cells counted. Cellular uptake of BrdU was identified
with EGF, explants cultured in basal medium and EKI- by staining with a biotin-conjugated monoclonal anti-
785, and explants cultured in basal medium to which body to BrdU (Zymed #03-3940, San Francisco, CA,
EGF and EKI-785 were added. A total of six to eight USA) followed by extraviden conjugated with alkaline
explants per experimental group were evaluated. phosphatase (Sigma #E2636).
The basal medium consisted of equal volumes of Dul-
becco’s modified Eagle’s medium and Ham’s F-12 me- Histology, immunohistology, and determination of
dium supplemented with insulin (8.3 3 1027 m), prosta- segmental nephron cyst localization
glandin E1 (7.1 3 1028 m), selenium (6.8 3 1029 m), Following 120 hours of incubation, intact explants from
transferrin (6.2 3 1028 m), triiodothyronine (2 3 1029 m),
control and treatment groups were assessed histologically.and dexamethasone (0.2 mg/liter).
Tissue was fixed in 4.0% paraformaldehyde in phosphateSupplemented medium consisted of the basal medium
buffer (pH 7.4) for 30 minutes at 48C. Explants wereto which either EGF (20 ng/ml), EKI-785 (0.1 to 1.0 nm),
then washed, dehydrated through graded acetone, andor EGF and EKI-785 were added. Concentrations were
embedded in Immunobede plastic embedding mediumdetermined from preliminary organ culture dose–response
(Polysciences, Warrington, PA, USA). Sections were cutexperiments that established the optimal concentrations
at 3 mm on an ultramicrotome, mounted on glass slidesof each supplement producing maximal biological effects
and stained with hematoxylin or segment-specific lectins.without tissue injury.
Segmental nephron cystic localization and cystic indexExplants from one kidney (group A) were paired with
were quantitated in each group by combining morpho-explants from the opposite kidney of the same animal
metric analysis with light microscopy and immunohisto-(group B) and were cultured under identical conditions
logical techniques [11, 25]. Cyst localization was studiedfor 120 hours. Explants from group A were evaluated
by segment-specific lectin binding using Dolichos biflorusby morphometric and immunohistochemistry methods
agglutinin (DBA) as a marker for CTs and Lotus tetra-to determine the degree of cyst formation (cyst index),
gonolobus (LTA) as a marker for proximal tubules.segment-specific cyst localization, and bromodeoxyuri-
The immunostaining procedure used was our previouslydine (BrdU) labeling index. The paired explants from
described postembedding technique specifically devel-the opposite kidney (group B) were evaluated for EGFR
oped for localization of antigens and lectins in plastictyrosine kinase activity by Western analysis.
sections [22]. Sections 3 mm thick were etched, trypsinized,Growth of metanephric explants was assessed follow-
and incubated overnight at 48C with biotinylated lectinsing 120 hours of incubation using the Bradford protein
[3.57 mg/ml for LTA (Sigma #L3134 and 6.25 mg/ml formicroassay [24]. Explant viability was assessed using pre-
DBA, Sigma #L6533)], followed by incubation with ex-viously described methods of cellular trypan blue exclu-
traviden peroxidase (1/400) for 90 minutes at room tem-sion and neutral red uptake [11]. Three kidneys from
perature. Sections were then stained with 0.05% diamino-each treatment group were used to determine protein
content and viability. benzidine and 0.01% hydrogen peroxide for 10 minutes
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and were counter-stained with hematoxylin. The num- equal amounts of total protein were immunoprecipitated
with 4.0 mg of anti–EGF-R (#sc-03; Santa Cruz Biotech-bers of LTA-positive and DBA-positive cysts as well as
the explant cystic index was determined in six to eight nology, Santa Cruz, CA, USA) for two hours at 48C.
Following incubation with anti–EGF-R, 25 ml of proteinexplants, with low-power magnification (320) by one
observer (W.E.S.) without knowledge of the experimen- A/G plus agarose (#sc2003; Santa Cruz Biotechnology)
were added to each supernatant sample to precipitatetal grouping.
resultant antibody-antigen complexes. The samples were
Cystic index incubated, with gentle rocking, overnight at 48C. Immu-
noprecipitates were collected by centrifugation, washed,The degree of tubular cyst formation was quantitated
by use of a cystic index. The index has been derived and processed for SDS-polyacrylamide gel electrophore-
sis (SDS-PAGE) in equal volumes. Immunoprecipitatesfrom basic light microscopic morphometric methods [25]
and has been standardized to quantitate cyst formation were stored at 2708C until resolved under reducing con-
ditions on 7.5% SDS-PAGE. Gels were loaded with equalin vivo and in vitro [11, 17, 22]. Following routine histo-
logical preparation, 10 to 12 evenly spaced 3 mm sections volumes of immunoprecipitated sample per lane for SDS-
PAGE, electrophoretically transferred to nitrocellulose,of explants were graded for cyst formation in LTA-posi-
tive tubular segments (PT) or in Dolichous Biflorus-posi- and probed with antiphosphotyrosine (RC-20-HPRO;
Transduction Laboratories, #E120H, Lexington, KY,tive tubular segments (CT) on the following scale [11,
12, 18, 20]: 0 5 no cysts observed; 1 5 single or multiple USA) and detected by enhanced chemiluminescence
(ECL; Amersham Life Science, Arlington Heights, IL,cysts , 0.05 mm; 2 5 multiple cysts . 0.05 mm # 0.01
mm; 3 5 multiple cysts . 0.01 mm # 0.15 mm; 4 5 USA).
multiple cysts . 0.15 mm # 0.20 mm; 5 5 multiple cysts .
Statistical analysis0.20 mm.
For each treatment group, a cystic index was deter- The data generated from various treatment groups
yielded a nonnormal distribution and were expressed asmined on a total of six explants.
mean values with ranges. The significance of differences
Demonstration of epidermal growth factor receptor between treatment groups was determined by the Wil-
tyrosine kinase activity coxon rank sum test [28].
Activated receptor was identified by measuring spe-
cific EGFR autophosphorylation through modifications
RESULTS
of the procedures of Honegger et al [26] and Donaldson
Organ culture morphology, growth, proliferation,and Cohen [27]. These modifications were established
and viabilityby evaluation of a dose response curve using varying con-
centrations of EGF and EKI-785, as well as varying incu- At the initiation of culture, control explants showed
the normal panorama of tubular and glomerular struc-bation times. Explants were then disrupted by homogeni-
zation with ice-cold RIPA buffer, containing NP-40 (1%), tures, whereas cystic explants showed prominent collect-
ing tubular dilations against a background of normalsodium deoxycholate (0.5%), sodium dodecyl sulfate
(SDS; 0.1%), aprotinin (100 mg/ml), leupeptin (5 mg/ml), nephron elements. (Fig. 1 A, B).
Following 120 hours of culture, explants in all groupspepstatin (50 mg/ml), ethylenediaminetetraacetic acid
(EDTA) 1 mm, phenylmethylsulfonyl fluoride (PMSF; demonstrated continued nephrogenesis without evi-
dence of necrosis. During culture, cystic explants in basal100 mg/ml), and sodium orthovanadate (1 mm). Cellular
debris was pelleted by centrifugation, and the superna- medium demonstrated regression of CT tubular cystic
lesions (Fig. 1D and Table 1). The cystic index of cystictant transferred to clean microfuge tubes. Protein con-
tent was determined by the method of Bradford [24], and explants cultured in basal medium decreased by 24%
c
Fig. 1. Representative photographs: explants of each of the experimental groups. Sections are DBA stained to identify collecting tubule (CT)
and are counterstained with hematoxylin (discussed in the main body of the text). (A) Control explant prior to culture. (B) Cystic explant prior
to culture. (C) Control explant following 120 hours of culture in basal medium. (D) Cystic explant following 120 hours of culture in basal medium.
Data demonstrate a slight regression in CT cystic lesions from an average preculture explant value of 3.5 (B) to postculture average cystic index
of 2.7 when cystic explants are cultured in basal medium. (E) This depicts control explants following 120 hours of culture in basal medium 1 EGF
(20 ng/ml). Explant demonstrates organotypic differentiation without morphological evidence of cellular damage. Explant also demonstrates no
CT (DBA1) cystic lesions. (F) Cystic explant following 120 hours of culture in basal medium 1 EGF (20 ng/ml) demonstrates that the addition
of EGF causes an increase in CT cystic lesions. (G) Control explant and (H) cystic explant following 120 hours of culture in basal medium 1
EGF (20 ng/ml) 1 EKI-785 (1.0 nm). Data demonstrate continued organotypic differentiation and growth without evidence of tubular damage or
epithelial toxicity in the presence of EKI-785. (H) This demonstrates that the addition of EKI-785 to basal medium 1 EGF causes a dramatic
decrease in CT cystic lesions compared with basal medium 1 EGF (F).
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Table 1. Cystic index and rate of growth of experimental groups
Experimental group Ct cystic index Growtha BrdU labelingb Viability
Control (Pre) 0 — — —
Cystic (Pre) 3.6 (3.3–3.9) — — —
Control 1 Basal 0 16 (13–18) 5 (3–8) 92 (91–94)
Cystic 1 Basal 2.7 (2.4–2.9) 12 (11–13) 8 (5–9) 94 (92–96)
Control 1 EGF 0 21 (18–22) 11 (7–12) 95 (94–97)
Cystic 1 EGF 4.3d (4.2–4.7) 26 (24–27) 21 (18–26) 96 (94–98)
Control 1 EGF 1 EKI-785 0 11 (9–12) 6 (4–7) 94 (93–94)
Cystic 1 EGF 1 EKI-785 1c (0.7–1.2) 12 (10–14) 10 (8–13) 97 (95–98)
Data demonstrate good growth of all exerimental groups and viabilities greater than 92%. Cystic index data demonstrate that addition of EKI-785 to basal 1
EGF medium causes a dramatic reduction of CT cystic lesions in cystic explants.
a Percent increase in protein content over protein content of pre-culture explant
b Brdu positive cells per 500 cells counted
c Cystic 1 EFG vs. Cystic 1 EGF 1 EKI-785, P , 0.024
d Cystic 1 Basal vs. Cystic 1 EGF, P , 0.05
from a preculture cystic index of 3.6 to a postculture reduction in CT cystic index compared with cystic ex-
plants treated with EGF alone, without significant reduc-cystic index of 2.7. The rate of growth of cystic explants
grown in basal medium was similar to the growth rate tion in explant growth or viability compared with ex-
plants cultured in basal medium (Fig. 1F and Table 1).of control explants cultured in basal medium, and the
viability of all explants was above 92%. (Table 1). Mor-
Receptor tyrosine kinase activityphologically, cystic explants cultured in basal medium
exhibited a variety of tubular and glomerular structural The effect of a range of EKI-785 concentrations on
CT cyst formation and EGFR tyrosine kinase activityelements indistinguishable from control explants cultured
in basal medium. (Fig. 1 C, D). was evaluated. Cystic index and receptor phosphoryla-
Control or cystic explants treated with EKI-785 (1 nm) tion levels were determined in paired explants from the
only demonstrated no distinguishable morphological ab- opposite kidneys of the same animal, cultured under
normalities and no difference in viability compared with identical conditions. Figure 2 demonstrates that increas-
basal treated tissue (data not shown). ing levels of EKI-785 resulted in a dose-dependent de-
Control explants treated with EGF showed a 31% crease in EGFR phosphorylation levels and a progressive
increase in growth compared with control explants with- decrease in explant CT cystic index.
out EGF but demonstrated no CT cysts after 120 hours of
culture (Table 1 and Fig. 1E). BrdU labeling of explants
DISCUSSIONtreated with EGF (Table 1) demonstrates increased cel-
Studies of the ontogeny of cyst formation in murinelular proliferation in explants treated with EGF alone
models of ARPKD and preliminary reports in humancompared with explants treated with EGF 1 EKI-785.
ARPKD have demonstrated two distinct phases in cysticThere was an approximate threefold increase in the pro-
nephron involvement (abstract; Sweeney and Avner, Jliferation of cystic explants treated with EGF compared
Am Soc Nephrol 9:383A, 1998) [15–17]. Initially, cysticwith cystic explants cultured in basal medium alone. The
lesions develop in distal portions of the proximal tubulesaddition of EKI-785 to cystic explants treated with EGF
(stage 1). As the cystic disease progresses, there is a shiftreduced the BrdU labeling rate to basal levels. Treat-
in the site of nephron involvement to the CT (stage 2).ment of cystic explants with EGF (20 ng/ml) resulted in
In order to study specific factors involved in the earlyacceleration of CT cyst formation/enlargement with a
stages of murine ARPKD, we have previously used an59% increase in CT cystic index compared with culture
in vitro murine metanephric culture system to studyin basal medium (Fig. 1F and Table 1). Prominent cystic
proximal tubule cyst development [11, 18, 20, 22]. Thislesions localized to DBA-positive CTs were noted amidst
serum-free system allows the examination of cyst forma-a background of normal in vitro organ culture structures
tion and enlargement in embryonic day 13 through new-without morphological evidence of tubular damage or
born kidneys. To study cyst pathogenesis in stage 2, theepithelial toxicity.
CT phase of murine ARPKD, in organ culture, it isControl explants treated with EGF (20 ng/ml) and
necessary to use more mature renal tissue. This studyEKI-785 (1 nm) demonstrated no distinguishable mor-
demonstrates that minor modifications of the previouslyphological abnormalities and no difference in viability
described organ culture system permit successful culturecompared with EGF or basal treated tissue (Fig. 1G and
of more mature renal tissue. The most significant modi-Table 1). Cystic explants treated with EGF (20 ng/ml)
fication involved the use of Transwellt tissue cultureand EKI-785 (1 nm; Fig. 1H) demonstrated a marked
reduction in CT cystic lesions with a greater than fourfold inserts in place of standard Trowell-type tissue culture
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Fig. 2. Western analysis of phosphorylated epidermal growth factor receptor (EGFR). Explant homogenates of equal protein levels were immuno-
precipated (IP) with anti-EGFR. IP residue was electrophoresed on a 7.5% denaturing gel, transferred to nitrocellulose, probed with antiphosphotyro-
sine (RC-20 Transduction Labs) and visualized by ECL (Amersham). Lane A, BPK P-14 cystic explant prior to culture. Lane B, BPK P-14 cystic
explant following 120 hours of culture in basal medium 1 EGF (20 ng/ml). Lane C, BPK P-14 cystic explant following 120 hours of culture in
basal medium 1 EGF (20 ng/ml) and a two-hour daily pulse of EKI-785 (0.1 nm). Lane D, BPK P-14 cystic explants following 120 hours of culture
in basal medium 1 EGF (20 ng/ml) and constant incubation of EKI-785 (0.1 nm). Lane E, BPK P-14 cystic explant following 120 hours of culture
in basal medium 1 EGF (20 ng/ml) and constant incubation of EKI-785 (1.0 nm). Lane F, control explant (unaffected) prior to culture. Lane G,
control explant (unaffected) following 120 hours of culture in basal medium 1 constant incubation with EKI-785 (0.1 nm). Lane H, control explant
(unaffected) following 120 hours of culture in basal medium 1 constant incubation with EKI-785 (1.0 nm). At the top of each lane, the collecting
tubule (CT) cystic index of each treatment group (discussed in the main body of the text) has been noted. The Western analysis demonstrates a
direct correlation between the cystic index and the level of phosphorylated EGFR.
assemblies, resulting in improved viability and increased activity by binding to the ATP binding site of EGFR [24].
EKI-785 inhibits: (a) the catalytic activity of the purifiedgrowth. The explants cultured on Transwell tissue cul-
ture inserts flattened out to a greater extent than those on EGFR kinase (IC50 5 420 pm), (b) autophosphorylation
of EGFR (IC50 5 5 nm), and (c) mitogenesis in a varietystandard Trowell assembly. This spreading presumably
permitted greater gas exchange and led to improved of cells that overexpress EGFR [24]. EKI-785 has also
been shown to inhibit c-erbB-2 activity.viability [29].
The advantage of such an in vitro system is that it Despite some conflicting reports [30, 31], there are
considerable data supporting the potential therapeuticpermits organotypic growth and differentiation of renal
tissue in serum-free–defined medium without perfusion, value of EGFR tyrosine kinase inhibition in decreasing
CT cyst formation and growth. These data include stud-filtration, or urine formation. It also experimentally iso-
lates the process of genetically determined renal cyst ies that demonstrate that the EGF/TGF-a/EGFR axis is
operative in CT cyst formation and growth. These studiesformation from the presence of cyst-promoting sub-
stances in serum, urine, or cyst fluid. In addition, the demonstrate that: (a) EGF and TGF-a are cystogenic in
a variety of in vitro systems [9, 11, 19]; (b) overexpressionorgan culture system can be used to rapidly screen poten-
tial therapeutic compounds for effects on both the proxi- of TGF-a in transgenic mice causes renal cystic abnor-
malities [5]; (c) cystic kidneys have increased TGF-amal and CT phases of cyst formation.
In this study, organ culture was used to examine the mRNA levels [32]; (d) cyst fluid from ADPKD, ARPKD,
rat and murine models of PKD contain immunoreactiveefficacy of a newly developed EGFR TKI (EKI-785) in
reducing CT cyst formation and growth in the BPK mu- EGF-like peptides in mitogenic quantities [3, 6, 7, 32];
(e) EGFR is overexpressed and mislocalized to the apicalrine model of ARPKD. EKI-785 is a new member of a
class of synthetic compounds designed to inhibit EGFR membrane of cystic epithelia in human ADPKD, human
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